[go: up one dir, main page]

MA33449B1 - Antigènes recombinants du vrs - Google Patents

Antigènes recombinants du vrs

Info

Publication number
MA33449B1
MA33449B1 MA34557A MA34557A MA33449B1 MA 33449 B1 MA33449 B1 MA 33449B1 MA 34557 A MA34557 A MA 34557A MA 34557 A MA34557 A MA 34557A MA 33449 B1 MA33449 B1 MA 33449B1
Authority
MA
Morocco
Prior art keywords
vrs
recombinant antigens
antigens
rsv
recombinant
Prior art date
Application number
MA34557A
Other languages
Arabic (ar)
English (en)
Inventor
Guy Jean Marie Fernand Pierre Baudoux
Normand Blais
Sonya L Cyr
Patrick Rheault
Jean Louis Ruelle
Original Assignee
Glaxosmithkline Biolog Sa
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42670494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33449(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa, Id Biomedical Corp Quebec filed Critical Glaxosmithkline Biolog Sa
Publication of MA33449B1 publication Critical patent/MA33449B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des antigènes recombinants du virus respiratoire syncytial (VRS) et leurs procédés de préparation et d'utilisation, y compris des compositions immunogènes (par exemple, des vaccins) pour le traitement et/ou la prévention d'une infection à VRS.
MA34557A 2009-06-24 2010-06-24 Antigènes recombinants du vrs MA33449B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21996409P 2009-06-24 2009-06-24
US33456810P 2010-05-13 2010-05-13
PCT/EP2010/059008 WO2010149745A1 (fr) 2009-06-24 2010-06-24 Antigènes recombinants du vrs

Publications (1)

Publication Number Publication Date
MA33449B1 true MA33449B1 (fr) 2012-07-03

Family

ID=42670494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34557A MA33449B1 (fr) 2009-06-24 2010-06-24 Antigènes recombinants du vrs

Country Status (29)

Country Link
US (1) US9492531B2 (fr)
EP (1) EP2445526B1 (fr)
JP (2) JP6062245B2 (fr)
KR (1) KR101696002B1 (fr)
CN (1) CN102481359B (fr)
AU (2) AU2010264688A1 (fr)
BR (1) BRPI1015917A2 (fr)
CA (1) CA2766211A1 (fr)
CL (1) CL2011003273A1 (fr)
CO (1) CO6480978A2 (fr)
CR (1) CR20120025A (fr)
CY (1) CY1117673T1 (fr)
DK (1) DK2445526T3 (fr)
DO (1) DOP2011000389A (fr)
EA (1) EA023054B1 (fr)
ES (1) ES2583257T3 (fr)
HR (1) HRP20160798T1 (fr)
HU (1) HUE028085T2 (fr)
IL (1) IL217013B (fr)
MA (1) MA33449B1 (fr)
MX (1) MX2012000035A (fr)
PE (1) PE20121541A1 (fr)
PL (1) PL2445526T3 (fr)
PT (1) PT2445526T (fr)
SG (1) SG176829A1 (fr)
SI (1) SI2445526T1 (fr)
UA (1) UA111141C2 (fr)
WO (1) WO2010149745A1 (fr)
ZA (1) ZA201109199B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
RU2531510C2 (ru) * 2008-12-09 2014-10-20 Новавакс, Инк. Модифицированные f протеины sv и способы их применения
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2012116715A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des nouveaux-nés et des enfants en bas âge
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
CN102294027A (zh) * 2011-07-26 2011-12-28 昆明理工大学 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法
WO2013031827A1 (fr) 2011-08-29 2013-03-07 国立大学法人徳島大学 Vaccin muqueux contre rsv
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
CN102743750B (zh) * 2012-07-09 2013-11-20 江苏省农业科学院 一种复方免疫增强剂、禽用疫苗及其制备方法
EA031453B1 (ru) 2012-08-01 2019-01-31 Бавариан Нордик А/С Рекомбинантный модифицированный вирус осповакцины анкара (mva) и его применение
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) * 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
WO2014160463A1 (fr) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines f de rsv pré-fusion et leur utilisation
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
EP2983708A4 (fr) * 2013-04-08 2016-10-05 Medimmune Llc Composition de vaccin et son procédé d'utilisation
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
BR112016028816A8 (pt) * 2014-06-13 2021-07-20 Glaxosmithkline Biologicals Sa combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
PT3393512T (pt) * 2015-12-23 2026-01-16 Pfizer Inc Mutantes de proteína f de rsv
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
WO2017207477A1 (fr) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Protéines f du vrs de pré-fusion solubles stabilisées
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
CN115442571A (zh) * 2016-09-23 2022-12-06 伊姆西Ip控股有限责任公司 用于视频监控系统的故障恢复方法和装置
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624844A1 (fr) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Procédés et compositions pour induire une immunité protectrice contre l'infection par le vrs
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
AU2018285412B2 (en) 2017-06-14 2022-06-23 Universität Zürich Cyclic peptides for protection against respiratory syncytial virus
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
WO2019202035A1 (fr) * 2018-04-17 2019-10-24 Curevac Ag Nouvelles molécules d'arn rsv et compositions pour vaccination
CA3107077A1 (fr) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processus et vaccins
EP3880243A1 (fr) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Protéines f du vrs sous forme pré-fusion stabilisées
CN113260377B (zh) 2018-12-20 2025-08-22 维罗米蒂克斯股份公司 脂肽构建块和合成病毒样颗粒
US12121578B2 (en) 2019-02-28 2024-10-22 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
EP4169513A1 (fr) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Composition d'adjuvant comprenant des agonistes du sting
CN115772230A (zh) * 2022-07-18 2023-03-10 青岛硕景生物科技有限公司 一种rsv重组抗原、其制备方法及应用
IL319340A (en) 2022-09-29 2025-05-01 Pfizer Immunogenic preparations containing RSV F protein truncation
CN120153078A (zh) 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
WO2024089634A1 (fr) 2022-10-27 2024-05-02 Pfizer Inc. Compositions immunogènes contre la grippe et le vrs
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびｒｓｖに対する免疫原性組成物
TW202436325A (zh) 2023-01-18 2024-09-16 美商輝瑞大藥廠 針對呼吸道疾病之疫苗
EP4644550A1 (fr) * 2023-03-17 2025-11-05 WestVac Biopharma Co., Ltd. Vaccin contre une infection par le virus respiratoire syncytial
WO2025012756A1 (fr) 2023-07-07 2025-01-16 Pfizer Inc. Adjuvants amphiphiles tlr7/8 et leurs utilisations
EP4520334A1 (fr) 2023-09-07 2025-03-12 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
WO2025052001A1 (fr) 2023-09-07 2025-03-13 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
WO2025126071A1 (fr) 2023-12-14 2025-06-19 Pfizer Inc. Molécules d'arn
WO2025163460A2 (fr) 2024-01-30 2025-08-07 Pfizer Inc. Vaccins contre des maladies respiratoires
WO2025186719A1 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Compositions immunogènes et leurs utilisations
WO2025263563A1 (fr) * 2024-06-20 2025-12-26 Ｋｍバイオロジクス株式会社 Vaccin à arnm chimérique du vrs fg
US20260021175A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
EP0396563B1 (fr) 1987-12-23 1993-02-10 The Upjohn Company Glycoproteines chimeriques contenant des segments immunogeniques des glycoproteines du virus syncytial respiratoire humain
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
KR960700271A (ko) 1993-01-08 1996-01-19 로렌스 티. 웰츠 인간 호흡계 합포체 바이러스 fg 당단백질의 정제 및 리폴딩 방법(process for the purification and refolding of human respiratory syncytial virus fg glycoprotein)
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
ATE287957T1 (de) 1997-09-19 2005-02-15 Wyeth Corp Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
DE69935330T2 (de) 1998-06-30 2007-10-31 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
CN100406060C (zh) 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
CA2435972C (fr) 2001-01-26 2011-09-13 University Of Lausanne Regions se liant a la matrice nucleaire (mar) et procedes d'utilisation de celles-ci
AU2002245636B2 (en) 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
CA2444130C (fr) 2001-04-17 2010-12-21 Sumitomo Pharmaceuticals Company, Limited Derives d'adenine
ES2318615T3 (es) 2001-11-16 2009-05-01 Coley Pharmaceutical Group, Inc. N-(4-(4-amino-2-etil-1h-imidazo(4,5-c)quinolin-1-il)butil)metanosulfonamida, una composicion farmaceutica que la comprende y uso de la misma.
EP1592302A4 (fr) 2003-02-13 2007-04-25 3M Innovative Properties Co Procedes et compositions associes a des composes modificateurs de reponse immunitaire et recepteur 8 de type toll
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
PL2287302T3 (pl) 2003-10-24 2013-05-31 Selexis Sa Wysokowydajny transfer genu i ekspresja w komórkach ssaczych przez procedurę wielokrotnej transfekcji sekwencji regionu przylegania do regionu
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2089515A4 (fr) * 2006-11-16 2011-02-23 Novavax Inc Particules de type viral (vlp) apparentees au virus respiratoire syncytial
WO2008114149A2 (fr) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Antigènes chimériques
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
CA2731194A1 (fr) 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Antigenes polypeptidiques chimeriques du virus respiratoire syncytial
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine

Also Published As

Publication number Publication date
PE20121541A1 (es) 2012-12-21
BRPI1015917A2 (pt) 2019-08-27
SI2445526T1 (sl) 2016-08-31
AU2014203636B2 (en) 2016-10-20
CR20120025A (es) 2012-05-28
EP2445526A1 (fr) 2012-05-02
AU2014203636C1 (en) 2017-02-09
CA2766211A1 (fr) 2010-12-29
EA023054B1 (ru) 2016-04-29
CN102481359A (zh) 2012-05-30
JP6062245B2 (ja) 2017-01-18
IL217013A0 (en) 2012-02-29
ZA201109199B (en) 2012-08-29
US9492531B2 (en) 2016-11-15
SG176829A1 (en) 2012-01-30
AU2014203636A1 (en) 2014-07-31
DK2445526T3 (en) 2016-06-27
ES2583257T3 (es) 2016-09-20
WO2010149745A1 (fr) 2010-12-29
CY1117673T1 (el) 2017-05-17
UA111141C2 (uk) 2016-04-11
EA201270063A1 (ru) 2012-07-30
JP2016128457A (ja) 2016-07-14
DOP2011000389A (es) 2012-04-30
MX2012000035A (es) 2012-02-28
HUE028085T2 (en) 2016-11-28
KR101696002B1 (ko) 2017-01-13
CN102481359B (zh) 2015-08-19
PL2445526T3 (pl) 2017-08-31
KR20120097472A (ko) 2012-09-04
CO6480978A2 (es) 2012-07-16
EP2445526B1 (fr) 2016-05-11
PT2445526T (pt) 2016-08-16
AU2010264688A1 (en) 2012-01-19
IL217013B (en) 2018-02-28
JP2012530504A (ja) 2012-12-06
CL2011003273A1 (es) 2012-10-19
HRP20160798T1 (hr) 2016-08-12
US20120093847A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MA33449B1 (fr) Antigènes recombinants du vrs
EA201070794A1 (ru) Рекомбинантные антигены rsv
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
UA103881C2 (ru) Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
MX345700B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
DK2315580T3 (da) Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
MA31500B1 (fr) Composes chimiques
WO2009060281A3 (fr) Analogues d'oligoribonucléotides immunostimulants contenant des fractions oligophosphates modifiées
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
MY186986A (en) Compositions and methods of use of phorbol esters
EA201290956A1 (ru) Вакцина против вич
MA31598B1 (fr) Composes antiviraux, compositions et leurs procedes d'utilisation
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
MX2009008495A (es) Novedosos analogos de nucleosidos para el tratamiento de infecciones virales.
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MY172788A (en) Influenza vaccines
MX2019012620A (es) Composiciones de vacunas.
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire